HENG and KOLLMANNSBERGER

s+%26+Virtual+Meeting/Abstracts?&vmview;=abst_detail_view&confID;=47&abstractID;=33225; cited January19, 2009]47. Rixe O, Bukowski RM, Michaelson MD, et al. Axitinib treat-ment in patients with cytokine-refractory metastatic renal-cellcancer: a phase ii study. lancet Oncol 2007;8:975–84.48. Hutson TE, Davis ID, Machiels JP, et al. Pazopanib(GW786034) is active in metastatic renal cell carcinoma (rcc):interim results of a phase ii randomized discontinuation trial(rdt) [abstract 5031]. J Clin Oncol 2007;25:. [Available onlineat: www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview;=abst_detail_view&confID;=47&abstra;ctID=33945; cited January 21, 2009]49. Sridhar SS, Hotte SJ, Mackenzie MJ, et al. Phase ii study ofthe angiogenesis inhibitor AZD2171 in first line, progressive,unresectable, advanced metastatic renal cell carcinoma (rcc):a trial of the pmh phase ii Consortium [abstract 5093]. J ClinOncol 2007;25:. [Available online at: www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview;=abst_detail_view&confID;=47&abstractID;=30404; cited January 21,2009]50. Yazji S, Bukowski R, Kondagunta V, Figlin R. Final resultsfrom phase ii study of volociximab, an a5B1 anti-integrinantibody, in refractory or relapsed metastatic clear cell re-nal cell carcinoma (mccrcc) [abstract 5094]. J Clin Oncol2007;25:. [Available online at: www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview;=abst_detail_view&confID;=47&abstractID;=32692; cited January 21, 2009]51. Delahunt B, Eble JN. Papillary renal cell carcinoma: a clini-copathologic and immunohistochemical study of 105 tumors.Mod Pathol 1997;10:537–44.52. Eder JP, Heath E, Appleman L, et al. Phase i experience withc-Met inhibitor XL880 administered orally to patients (pts) withsolid tumors [abstract 3526]. J Clin Oncol 2007;25:. [Availableonline at: www.asco.org/ASCO/Abstracts+%26 +Virtual +Meeting/Abstracts?&vmview;=abst_detail_view&confID;=47&abstractID;=35460; cited January 21, 2009]53. Garcia A, Rosen L, Cunningham CC, et al. Phase 1 study of ARQ 197, a selective inhibitor of the c-Met rtk in patients with metastatic solid tumors reaches recommended phase 2 dose [abstract 3525]. J Clin Oncol 2007;25:. [Available online at: www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview;=abst_detail_view&confID;=47&abstra;ctID=35755; cited January 21, 2009]54. Srinivasan R, Choueiri TK, Vaishampayan U, et al. A phase iistudy of the dual Met/vegfr2 inhibitor XL880 in patients (pts)with papillary renal carcinoma (prc) [abstract 5103]. J Clin Oncol2008;26:. [Available online at: www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview; =abst_detail_view&confID;=55&abstractID;=36179; cited January 21, 2009]55. Shepard DR, Rini BI, Garcia JA, et al. A multicenter prospectivetrial of sorafenib in patients (pts) with metastatic clear cell renalcell carcinoma (mccrcc) refractory to prior sunitinib or bevaci-zumab [abstract 5123]. J Clin Oncol 2008;26:. [Available onlineat: www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview;=abst_detail_view&confID;=55&abstra;ctID=35252; cited January 21, 2009]56. Cooney MM, Garcia J, Brell J, et al. A phase i study of bevaci-zumab in combination with sunitinib in advanced solid tumors[abstract 15532]. J Clin Oncol 2007;25:. [Available onlineat: www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview;=abst_detail_view&confID;=47&abstra;ctID=32668; cited January 21, 2009]57. Feldman DR, Kondagunta GV, Ronnen EA, et al. Phase i trial ofbevacizumab plus sunitinib in patients (pts) with metastatic renalcell carcinoma (mrcc) [abstract 5099]. J Clin Oncol 2007;25:.[Available online at: www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview;=abst_detail_view&confID;=47&abstractID;=30852; cited January 21, 2009] Correspondence to: Christian Kollmannsberger, BCCancer Agency, 600 West 10th Avenue, Vancouver,British Columbia V5Z 4E6.E-mail: [email protected]* Medical Oncology, Tom Baker Cancer Center,Calgary, AB.† Medical Oncology, BC Cancer Agency, Vancouver,BC.